The Falutz phase 3 trials

The pivotal evidence: what the phase 3 program actually showed

Tesamorelin is unusual among peptides because its approval rests on genuine phase 3 randomized trials. The Falutz program tested it against placebo in hundreds of patients and produced the visceral-fat result that the entire indication stands on.

This unit walks the trial design, the primary visceral-fat endpoint, the secondary metabolic outcomes, the pooled 52-week extension that showed the effect is durable but reversible, and the modern-era confirmation.